ExOne Showcases Ability to 3D Print Virtually Any Powder Material in New Corporate Video, “Let’s Make it Right”
20.10.2021 14:30:00 CEST | Business Wire | Press Release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that it is open to developing virtually any powder material in partnership with manufacturers for their specific application.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005203/en/
The ExOne Company has released a new corporate video, "Let's Make it Right," showcasing the ability of its sustainable binder jetting technology to 3D print virtually any type of powder. ExOne has already qualified more than 20 metals, ceramics and composites for 3D printing, but is now developing materials such as pulverized concrete and other waste products with customers. (Photo: Business Wire)
The material flexibility and sustainability of ExOne’s patented binder jet 3D printing technology is showcased in a new corporate video unveiled today, “Let’s Make it Right.” The video is a celebration of ExOne’s employees and their accomplishments over more than 20 years as the company prepares to be acquired by Desktop Metal.
Beginning in the mid-1990s, ExOne pioneered the commercial development of MIT’s patented binder jet 3D printing process, which transforms powdered materials into precision parts or tooling at high speeds. An industrial printhead selectively deposits binder into a bed of powder particles creating a solid part one layer at a time, just like printing on sheets of paper.
The company’s RTS-300, launched in 1998, was the first commercially available metal binder jet system. ExOne later began binder jetting sand for metalcasting molds and cores. Today, ExOne has a portfolio of eight sand and metal 3D printing systems that can print a wide range of powders into highly dense parts, or even parts with controlled porosity, for specific applications.
“Binder jet 3D printing is one of the few additive manufacturing technologies that holds the promise of being an all-purpose manufacturing tool; it can print just about any powdered material into any form or functional purpose. In recent years, advancements in machine design and binder chemistries have helped us take a leap closer to that ultimate goal,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We are thankful to all of our former and current employees, as well as our R&D partners around the world, who have helped us advance binder jetting to where it is today and continue to support development efforts around this important green technology.”
Unique Material Flexibility in 3D Printing
Binder jetting is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as broad material flexibility, which is just beginning to be untapped because of ExOne’s improvements in machine design and binder chemistries.
To achieve high-density parts, such as metals, the printed part is typically sintered in a furnace to fuse the particles together into a high-density solid object. Porous parts, often created with sand or other large-particle media, can also be infiltrated with resins or metals to achieve desired properties and create unique composites.
Two new case studies illustrate the broad range of ExOne’s binder jetting technology beyond traditional industrial applications:
- Luxury sound system company, Deeptime, manufactures its speakers with 3D printed sand that is infiltrated with a proprietary solution to deliver material properties that are 86% more rigid than MDF, leading to double the sound damping compared to traditional speakers and much higher performance.
- Carnegie Mellon University’s School of Architecture, meanwhile, is developing binder jetting of pulverized concrete and other recycled materials that are then infiltrated with resins for use as durable outdoor architectural pieces. This approach represents the future of cradle-to-grave, ecologically intelligent building design.
ExOne’s resin-infiltrated sand 3D printing for architectural restoration was a finalist in the 2021 Awards for Composites Excellence at CAMX, the Composites and Advanced Materials Expo.
Full Flexibility of Binder Jet 3D Printing
Among the broad categories of materials that ExOne can now develop to manufacturer specifications:
- Aluminum alloys
- Carbides
- Copper and copper alloys
- Nickel alloys
- Nitrides
- Oxides
- Precious metal alloys, including silver and gold
- Refractory metals, such as tungsten and molybdenum alloys
- Sands
- Stainless steels, such as 17-4PH, 316L and 304L
- Titanium alloys, such as Ti64
- Tool steels, such as M2 and H13
- Waste products such as concrete and more
ExOne’s new corporate video is available at www.exone.com/MakeitRight.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005203/en/
Contact information
Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
